A new study published online in Archives of Facial Plastic Surgery suggests Dysport (abobotulinumtoxinA) is better for treating Crow’s feet than Botox (onabotulinumtoxinA).
Let’s look at the study in which 90 patients, all older than 18 years of age (mean age 54½, 77 women), were enrolled in a randomized, double-blind, split-face study.
The authors include this history of both products:
"…in 2002, the FDA approved Botox Cosmetic (onabotulinumtoxinA) (Allergan Inc, Irvine, California) for the treatment of corrugator-mediated glabellar lines.
"Concurrently, another botulinum toxin type A product manufactured by Medicis Aesthetics (Scottsdale, Arizona), Dysport (abobotulinumtoxinA), had been used in other countries since 1991. It was approved for cosmetic use in Europe in 2001, before being approved by the FDA in April 2009 for the treatment of moderate-to-severe glabellar lines.
"Today, the cosmetic applications for onabotulinumtoxinA and abobotulinumtoxinA have expanded to the treatment of hyperfunctional lines related to the orbicularis oculi, frontalis, transverse nasalis, and depressor anguli oris, among other muscle groups."
The 90 patients were seen and treated between December 2009 to August 2010. To be included in the study, the men (n=13) and women (n=77) had to have moderate to severe lateral orbital rhytids at maximal contraction and not had botulinum neuromodulator treatment to the crow’s feet within the prior 6 months.
Other exclusion criteria included: prior facelift, browlift, or blepharoplasty; prior periocular laser or chemical resurfacing; prior adverse reaction associated with botulinum neuromodulator; or a history of degenerative neuromuscular diseases.
[Source: Suture for a Living]